Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM — Stella

Home/Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions/Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

View on ClinicalTrials.gov

Recruiting

Back to Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions trials

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Early testing / Safety & dosing

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

Hebei Taihe Chunyu Biotechnology Co., Ltd

Enrollment target

~50 participants

Started

March 2025

Primary completion

March 2028

Age range

18 Years – 70 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.